Envestnet Asset Management Inc. Sells 5,809 Shares of Repligen Co. (NASDAQ:RGEN)

Envestnet Asset Management Inc. trimmed its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,442 shares of the biotechnology company's stock after selling 5,809 shares during the quarter. Envestnet Asset Management Inc. owned 0.19% of Repligen worth $15,321,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Ballentine Partners LLC raised its stake in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after buying an additional 72 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 81 shares during the period. MML Investors Services LLC boosted its position in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of a number of research reports. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Thursday. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $176.82.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Repligen Trading Down 1.6 %

NASDAQ:RGEN traded down $2.10 on Friday, hitting $130.00. 753,355 shares of the stock were exchanged, compared to its average volume of 707,222. The stock has a market cap of $7.30 billion, a PE ratio of -254.90, a PEG ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The stock has a fifty day moving average of $140.76 and a 200-day moving average of $145.82.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.